This extension to the CONSORT Statement provides a minimum list of essential items, that authors should consider when reporting the main results of a randomized trial in any journal or conference abstract. Clear, transparent, and sufficiently detailed abstracts of conferences and journal articles are important, because readers often base their assessment of a trial on such information. Some readers use an abstract to decide whether to seek more information about a trial. However, in some parts of the world, readers often have access to the abstracts only, so health-care decisions may be made on the basis of abstracts of randomized trials. When a trial is reported at a conference, the abstract might provide the only permanent information accessible to most readers.

A collection of examples on using the CONSORT for Abstracts checklist has been provided as well.

Available Downloads

There is no flow diagram for this extension.

Document Word Format PDF Format
Statement Document n/a Download
Checklist Download Download
Explanation & Elaboration n/a Download


Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF and the CONSORT Group (2008) CONSORT for reporting randomised trials in journal and conference abstracts. Lancet: 371:281-283. PMID: 18221781

Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF and the CONSORT Group (2008) CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med 5(1): e20. PMID: 18215107

Extensions of the CONSORT Statement

The main CONSORT Statement is based on the "standard" two-group parallel design. However, there are several variations to the standard trial methodology, including different design aspects (e.g., cluster), interventions (e.g., herbals) and data (e.g., harms).

To help improve the reporting of these trials the main CONSORT Statement has been extended and modified by members of the CONSORT group for application in these various areas. The resulting CONSORT extensions are presented in this section. This list is, by no means, exhaustive; and work is constantly in progress.

Please note that modifications to the CONSORT checklist or flow diagram that are not developed with the involvement of the CONSORT Group do not have permission to name their work "CONSORT".

Some work, however, has been done to modify the CONSORT Statement without the involvement of the Group. These unofficial extensions of the CONSORT Statement can be found here.


Finding the Appropriate Extension

The table below lists the current official extensions of the CONSORT statement.  You can click on each extension to learn more about it or to explore that extension in the checklist viewer application.


Cluster Trials Herbal Medicinal Interventions CONSORT-PRO
Non-Inferiority and Equivalence Trials Non-Pharmacologic Treatment Interventions Harms
Pragmatic Trials Acupuncture Interventions


N-of-1 Trials Chinese Herbal Medicine Formulas Equity
Pilot and Feasibility Trials  Social and Psychological Interventions Randomised Crossover Trial Reporting
Within Person Trials    
Multi-Arm Parallel-Group Randomized Trials    
Adaptive Designs